Clinical Trial Update: Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating doxorubicin and cyclophosphamide plus paclitaxel with or without trastuzumab in node-positive, HER2-overexpressing breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: NSABP Foundation Inc | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED